<DOC>
	<DOCNO>NCT00857896</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics , safety , tolerability fesoterodine follow administration pediatric patient , age 8-17 year , overactive bladder .</brief_summary>
	<brief_title>Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>A total body weight &gt; 25 kg ( 55 lb ) . Symptoms urinary frequency ( average â‰¥8 daily bathroom visit urinate ) urgency urinate , without urgency incontinence , least 6 month prior enrolment , OR Stable neurological disease urodynamically confirm detrusor overactivity , may require intermittent catheterization management urinary drainage . Treatment investigational drug within 4 week 5 halflives , whichever longer , first study dose Ongoing use potent CYP3A4 inhibitor inducer CYP2D6 inhibitor Ongoing use another drug treat overactive bladder Uncontrolled narrow angle glaucoma , urinary gastric retention</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Study fesoterodine pediatric overactive bladder patient</keyword>
</DOC>